Importantly, we demonstrated that a high expression of BIRC5 is indicative of a bad prognosis of NB-therapy and indicative of lower survival of the high-risk NB patients and these high levels of BIRC5 can be suppressed by overexpression of RUNX1. Here, RUNX1 is linked to neuroblastoma.